Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Agios Pharmaceuticals, Inc. reported revenue of $54M, up 48.0% year over year. Operating margin was -873.9% and net margin -764.0%, on a free-cash-flow margin of -698.3% with capital expenditure at 8.0% of revenue. Every figure is computed directly from AGIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $54M | -873.9% | -764.0% |
| FY2024 | $36M | -1166.5% | 1845.9% |
| FY2023 | $27M | -1459.5% | -1312.6% |
| FY2022 | $14M | -2732.1% | -1627.8% |
| FY2021 | $0M | n/a | n/a |
How does AGIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · ABT · AMGN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.